Hilary B. Whitlatch, MD

• University of Connecticut, BS, Molecular and Cell Biology, 1999

• Tufts University School of Medicine, MD,  2003     

• Residency, Internal Medicine, Beth Israel Deaconess Medical Center, 2006

• Fellowship, Diabetes, Endocrinology & Metabolism, Rhode Island Hospital/Brown 2009

Hilary Whitlatch, MD is an Assistant Professor of Medicine at the University of Maryland School of Medicine in the Division of Endocrinology, Diabetes and Nutrition. She is an experienced clinician and treats a wide variety of endocrinologic conditions, including diabetes, pituitary, metabolic bone and thyroid disorders. She heads the Metabolic Bone Disease Clinic at UMMC Center for Diabetes and Endocrinology. She recently established a Transplant Endocrinology Clinic with the goal of improving patient access to endocrinologic care following kidney transplant.

Dr. Whitlatch’s clinical research interests include management of metabolic bone disease and treatment of severe insulin resistance. She has also investigated the use of various biomarkers in diabetes-related microvascular and macrovascular complication risk assessment.

Metabolic bone disease, parathyroid disease, adrenal disease, thyroid disease, insulin resistance.

Malandrino N, Wu WC, Taveira TH, Whitlatch HB, Smith RJ. Association between Red Blood Cell Distribution width and Macrovascular and Microvascular Complications in Diabetes. Diabetologia. 2012 Jan; 55(1):226-35. Epub 2011 Oct 15

Patel N, Taveira TH, Choudhary G, Whitlatch H, Wu WC. Fasting serum C-peptide levels predict diabetic and cardiovascular death in non-diabetic adults. J Am Heart Assoc. 2012; 1(6) Epub 2012 Dec 19

Sathya B, Davis, R, Taveira T, Whitlatch H, Wu WC. Intensity of peri-operative glycemic control and postoperative outcomes in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract Epub 2013 June 6